Last reviewed · How we verify

NCT04522336

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

Active, enrolled Phase 1 Last updated 5 March 2026
What this trial tests

Phase 1 trial testing Docetaxel in Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 in 16 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
16 September 2020
Primary endpoint
18 July 2027
18 July 2027

Quick facts

Lead sponsorM.D. Anderson Cancer Center
PhasePhase 1
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment16
Start date16 September 2020
Primary completion18 July 2027
Estimated completion18 July 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 or Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I trial investigates how well pembrolizumab and chemoradiotherapy works in treating patients with gastroesophageal cancer that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as fluorouracil, oxaliplatin and docetaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Giving pembrolizumab together with chemoradiotherapy may help to control gastroesophageal cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer.
    Li N, Sohal D. · · 2023 · cited 22× · PMID 37995002 · DOI 10.1007/s00262-023-03566-5
  2. Update of latest data for combined therapy for esophageal cancer using radiotherapy and immunotherapy: A focus on efficacy, safety, and biomarkers.
    Cheng S, Li B, Yu J, Wang L. · · 2023 · cited 6× · PMID 37969961 · DOI 10.21147/j.issn.1000-9604.2023.05.06

Verify or expand the search:

Other trials of Docetaxel

Trials testing the same drug.

Other recruiting trials for Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8

Currently open trials in the same condition.

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04522336.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing